For instance, palbociclib and abemaciclib, which are inhibitors of the cell cycle-related kinases CDK4 and CDK6, show an anti-tumor effect in a patient-derived xenograft (PDX) model of head and neck squamous cell carcinoma (HNSCC) [15]. Here, CDK4 is linked to head and neck squamous cell carcinoma.